Evidence map›Paper›PMID 39789996›Full record

ArticleCancer science2025

LHPP-P38 MAPK/ERK-ETS1 Axis Negative Feedback Signaling Restrains Progression in Breast Cancer.

Xu Liu, Deyang Yu, Zhen Yu, Sisi Su, Meixia Jiang, Chunbo Zhao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xu LiuAbdominal Radiotherapy Department, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin, Heilongjiang Province, China.
Deyang YuRadiophysics Department, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin, Heilongjiang Province, China.
Zhen YuAbdominal Radiotherapy Department, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin, Heilongjiang Province, China.
Sisi SuAbdominal Radiotherapy Department, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin, Heilongjiang Province, China.
Meixia JiangAbdominal Radiotherapy Department, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin, Heilongjiang Province, China.
Chunbo ZhaoAbdominal Radiotherapy Department, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin, Heilongjiang Province, China.ORCID https://orcid.org/0000-0003-1142-8128

Funding

Educational Scientific Research Topic SYY20240005Haiyan Fund Major Projects JJZD2023-03HMU Cancer Hospital Haiyan Fund Outstanding Youth Project JJYQ2024-05National Natural Science Foundation of China 82303432
6 · The paper itself

Abstract

Invasion and metastasis are major causes of mortality in breast cancer (BRCA) patients. LHPP, known for its tumor-suppressive effects, has an undefined role in BRCA. We found reduced LHPP protein in BRCA tissues, with lower levels correlating with poor patient outcomes. In vitro studies show LHPP inhibits BRCA cell proliferation, migration, invasion, and stemness. In vivo xenograft models support LHPP's role in curbing tumorigenesis and lung metastasis. Mechanistically, LHPP interacts with ERK and P38 MAPK, leading to their dephosphorylation and suppression of the MAPK pathway. We also reveal ETS1, a MAPK effector, repressing LHPP mRNA transcription, suggesting a LHPP-P38 MAPK/ERK-ETS1 negative feedback loop as a key regulatory mechanism in controlling BRCA invasion and metastasis.

Indexed as

Breast NeoplasmsMAP Kinase Signaling SystemAnimalsCell Line, TumorCell MovementCell ProliferationDisease ProgressionFemaleHumansInorganic PyrophosphataseMiceMice, Inbred BALB CNeoplasm InvasivenessNeoplastic Stem CellsProto-Oncogene Protein c-ets-1ETS1 protein, humanInorganic Pyrophosphatasephospholysine phosphohistidine inorganic pyrophosphate phosphatase, humanProto-Oncogene Protein c-ets-1breast cancerETS1LHPPmetastasisP38 MAPK/ERK

Identifiers

PMID39789996
PMCPMC11967269

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.